

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence

Ira Jacobs, Danielle Petersel, Lesley G. Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch, Sadiq Lula

Corresponding author: Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA. Email: ira.jacobs@pfizer.com

Supplemental Table S2. Publication categories for included articles

	Empirical articles of named and unnamed biosimilars	Non-empirical articles
Therapy area	Oncology Chronic inflammatory disease Other Not-specified	Oncology Chronic inflammatory disease Other Not-specified
Empirical study classification	RCT (PK/safety and efficacy)* Observational [prospective/retrospective] Post-marketing Nonclinical Analytical Health Economics Other*	N/A
Non-empirical study classification	N/A	Development and production <ul style="list-style-type: none"> Biosimilar development Manufacturing or supply Supply, quality, or methods Market analysis and uptake <ul style="list-style-type: none"> Attitudes or Education Economics or Pricing Guidelines Substitution or Interchangeability Terminology or Naming Overview <ul style="list-style-type: none"> General Overview Geographical Overview Therapy Area Overview Regulation and safety <ul style="list-style-type: none"> Regulatory or Policy Safety/Pharmacovigilance Other [†]

*Includes non-randomized safety/PK studies in healthy subjects.

[†]Other category includes any other publication on the topic of biosimilars provided that it is not one of the excluded empirical/non-empirical publication types.

N/A not applicable; PK pharmacokinetics; RCT randomized controlled trial.